HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.

AbstractBACKGROUND:
Alpha fetoprotein (AFP) is an oncofetal antigen over-expressed by many hepatocellular cancers (HCC). We previously demonstrated that HLA-A2-restricted epitopes derived from AFP are immunogenic in vitro and in vivo despite high circulating levels of this oncofetal antigen. In order to test a more broadly applicable, HLA-unrestricted, inexpensive, cell-free vaccine platform capable of activating tumor antigen-specific CD8+ and CD4+ T cells, we tested full length AFP in a plasmid DNA construct in combination with an AFP-expressing replication-deficient adenovirus (AdV) in a prime-boost vaccine strategy.
METHODS:
HCC patients who had an AFP+ tumor and previous treatment for HCC were screened and two patients received vaccination with three plasmid DNA injections followed by a single AdV injection, all delivered intramuscularly (i.m.).
RESULTS:
The vaccine was well tolerated and safe. Both patients showed immunologic evidence of immunization. The first patient had a weak AFP-specific T cell response, a strong AdV-specific cellular response and recurred with an AFP-expressing HCC at nine months. The second patient developed a strong AFP-specific CD8+ and CD4+ cellular response and an AdV neutralizing antibody response, and recurred at 18 months without an increase in serum AFP.
CONCLUSIONS:
The AFP DNA prime-AdV boost vaccine was safe and immunogenic. Circulating anti-AdV neutralizing antibodies at baseline did not prohibit the development of AFP-specific cellular immunity. The patient who developed CD8+ and CD4+ AFP-specific T cell immunity had more favorable progression-free survival. The observations with these two patients support development of this vaccine strategy in a larger clinical trial.
TRIAL REGISTRATION:
ClinicalTrials.gov: NCT00093548.
AuthorsLisa H Butterfield, James S Economou, T Clark Gamblin, David A Geller
JournalJournal of translational medicine (J Transl Med) Vol. 12 Pg. 86 (Apr 05 2014) ISSN: 1479-5876 [Electronic] England
PMID24708667 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Cancer Vaccines
  • Chemokines
  • Cytokines
  • Growth Substances
  • Vaccines, DNA
  • alpha-Fetoproteins
Topics
  • Adenoviridae (immunology)
  • Antibody Formation
  • Cancer Vaccines (administration & dosage)
  • Carcinoma, Hepatocellular (immunology)
  • Chemokines (blood)
  • Cytokines (blood)
  • Enzyme-Linked Immunosorbent Assay
  • Growth Substances (blood)
  • Humans
  • Liver Neoplasms (immunology)
  • Vaccines, DNA (administration & dosage)
  • alpha-Fetoproteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: